BLOG

Boehringer, OSE tie up in I-O deal that could total more than $1.4B

Boehringer Ingelheim and OSE Immunotherapeutics are partnering to develop the latter’s checkpoint inhibitor, OSE-172, for the treatment of advanced solid tumors.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}